Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
XTX101 is an anti-CTLA4 antibody engineered for tumor microenvironment-specific activity, which may lead to proliferation of CD8+ T lymphocytes, activation of T lymphocyte function, and tumor regression (Journal for ImmunoTherapy of Cancer 2020;8)
|DrugClasses||CTLA4 Antibody 21|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Pembrolizumab + XTX101||Pembrolizumab XTX101||0||1|